Academic Journal
Q1Journal of Hepatology
About Journal of Hepatology
Journal of Hepatology is a scholarly journal published by Elsevier B.V.. SCImago 2025 places it in Q1 with an SJR of 13.097 and an H-index of 338.
Its listed coverage is 1985-2026 and its research categories include Hepatology (Q1). The 2025 dataset reports 512 documents and 21804 citations across the latest three-year reporting window.
The Journal of Hepatology is a premier peer-reviewed medical journal dedicated to advancing the science and clinical practice of hepatology—the study of liver, gallbladder, biliary tree, and pancreas disorders. Published by Elsevier on behalf of the European Association for the Study of the Liver (EASL), the journal has earned global recognition for its high-impact research and authoritative reviews. It stands as a trusted resource for hepatologists, gastroenterologists, researchers, and healthcare professionals worldwide.
A High-Impact Journal with Global Reach
Established in 1985, the Journal of Hepatology has grown into one of the most respected publications in liver-related medical research. With an impressive impact factor—consistently ranking among the top journals in gastroenterology and hepatology—it attracts cutting-edge studies and insightful commentaries. The journal’s rigorous peer-review process ensures that only the highest-quality scientific content is published.
As a leading source for the latest developments in liver research, the journal covers a broad spectrum of topics, including liver cirrhosis, hepatitis, fatty liver disease (NAFLD/NASH), liver cancer, liver transplantation, and more. Each issue features original research articles, clinical trials, meta-analyses, reviews, and expert opinion pieces that contribute to better understanding and treatment of liver diseases.
Why the Journal of Hepatology Stands Out
One of the core strengths of the Journal of Hepatology is its commitment to scientific integrity and clinical relevance. The journal serves as a platform for both basic and translational research, bridging the gap between laboratory discoveries and clinical application. It provides valuable insights for academics, clinicians, and policy-makers alike.
Moreover, the journal is supported by EASL’s mission to promote liver health and foster international collaboration in the field of hepatology. With its global editorial board composed of leading experts, the Journal of Hepatology offers a truly international perspective on liver disease management.
Key Features:
-
Peer-Reviewed Excellence: All submissions undergo a meticulous review process, ensuring scientific accuracy and clinical relevance.
-
Open Access Options: Authors can choose to make their articles available to a wider audience through open-access publishing.
-
Latest Clinical Guidelines: The journal often features updated EASL guidelines and consensus statements, making it a go-to reference for hepatology practices.
-
Cutting-Edge Research: Topics range from viral hepatitis to liver transplantation and hepatocellular carcinoma, keeping readers informed of the latest advances.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The Journal of Hepatology is a leading peer-reviewed publication dedicated to the field of hepatology, offering a comprehensive platform for the latest scientific research, clinical studies, and innovations related to liver health. As the official journal of the European Association for the Study of the Liver (EASL), it plays a crucial role in advancing knowledge and understanding of liver diseases, their diagnosis, treatment, and prevention.
A Comprehensive Platform for Hepatology Research
The scope of the Journal of Hepatology is broad, covering all aspects of liver disease, including but not limited to:
-
Hepatitis (A, B, C, D, and E)
-
Cirrhosis and liver fibrosis
-
Non-alcoholic fatty liver disease (NAFLD)
-
Alcohol-related liver disease
-
Liver transplantation
-
Hepatocellular carcinoma (HCC)
-
Cholestatic and autoimmune liver diseases
-
Pediatric liver diseases
By embracing both clinical and basic research, the journal ensures that readers—from clinicians to researchers—stay updated on cutting-edge developments in hepatology.
Bridging Basic Science and Clinical Practice
One of the defining features of the Journal of Hepatology is its commitment to integrating basic scientific discoveries with clinical applications. It encourages the submission of translational research that bridges the gap between laboratory findings and patient care. Studies involving molecular biology, genetics, immunology, pharmacology, and epidemiology that contribute to the understanding of liver function and disease progression are highly welcomed.
Peer-Reviewed, High-Impact Publications
All submissions to the Journal of Hepatology undergo a rigorous peer-review process to ensure the highest standards of scientific integrity and relevance. The journal publishes a variety of article types, including:
-
Original research articles
-
Reviews and meta-analyses
-
Clinical trial reports
-
Case studies
-
Editorials and expert opinions
These articles contribute significantly to global hepatology literature and often influence clinical guidelines and treatment protocols.
Global Reach and Accessibility
With an international readership and contributors from all over the world, the Journal of Hepatology fosters global collaboration in liver disease research. Its high impact factor and wide indexing make it a preferred source of information for healthcare professionals, academicians, and students specializing in hepatology and gastroenterology.
A Trusted Resource for Liver Specialists
Whether you’re a hepatologist, gastroenterologist, researcher, or medical student, the Journal of Hepatology serves as a reliable resource to stay informed about the latest trends, therapies, and innovations in liver care. It is also instrumental for those involved in policy-making, public health, and pharmaceutical development related to liver disease.
Recent Research Articles
Latest publications matched automatically by ISSN.
Exercise-induced liver-to-brain communication in aging and Alzheimer’s disease
Valerie Chew
2026-09 · DOI: 10.1016/j.jhep.2026.06.003Delphi consensus in primary biliary cholangitis: Collective introspection to set a path forward
David N. Assis
2026-09 · DOI: 10.1016/j.jhep.2026.07.010Extended longitudinal validation of serum procalcitonin as a biomarker for fibrolamellar hepatocellular carcinoma
Lorenz Kocheise, Moritz Waldmann, Henrike Salié, Tarik Ghadban et al.
2026-09 · DOI: 10.1016/j.jhep.2026.04.031Redefining healthy human liver zonation using high-resolution spatial multiomics
Prakash Ramachandran
2026-09 · DOI: 10.1016/j.jhep.2026.07.002Comment on “Serum procalcitonin: A novel tumor biomarker for … fibrolamellar hepatocellular carcinoma”
İlgin Özden
2026-09 · DOI: 10.1016/j.jhep.2026.02.022Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid
Hai-Lin Xiong, Qi Zhao, Shu-Qing Liu, Li-Lin Chen et al.
2026-09 · DOI: 10.1016/j.jhep.2026.05.001Applications for the EASL Schools 2027 close on 28 September. Discover them!
2026-09 · DOI: 10.1016/s0168-8278(26)02726-1EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis
Cynthia Levy, Ana Lleo, Adrielly Martins, Miki Scaravaglio et al.
2026-09 · DOI: 10.1016/j.jhep.2026.03.038Retraction notice to “Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population” [J Hepatol 58 (2013) 271–277]
Qi Ling, Haiyang Xie, Di Lu, Xuyong Wei et al.
2026-09 · DOI: 10.1016/j.jhep.2026.06.002Post-Transplant Hepatitis D Breakthrough Driven by Integrant-Derived HBsAg from an Extrahepatic HCC Metastasis
Lorenza Di Marco, Nicola De Maria, Daniele Lombardo, Giovanni Raimondo et al.
2026-09 · DOI: 10.1016/j.jhep.2026.08.029Refining risk stratification and care pathways in pediatric MASLD
Yongzhen Zhang, Wenfang Li
2026-09 · DOI: 10.1016/j.jhep.2026.03.047Optimising the screening strategy for early-stage hepatocellular carcinoma
Lisa Sandmann
2026-09 · DOI: 10.1016/j.jhep.2026.06.016Submit your abstract for the EASL Steatotic Liver Disease Summit 2027 by 17 November!
2026-09 · DOI: 10.1016/s0168-8278(26)02725-x144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial
Heiner Wedemeyer, Soo Aleman, Antje Blank, Pietro Andreone et al.
2026-09 · DOI: 10.1016/j.jhep.2026.03.046Fusobacterium nucleatum alleviates alcohol-associated liver disease through mannose-mediated elevation of Fbp1 and modulation of gut microbiota
Hang Shu, Dongqing Wu, Linxi Xie, Gaoyuan Wang et al.
2026-09 · DOI: 10.1016/j.jhep.2026.04.001Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis
Lukas Van Melkebeke, Markus Boesch, Tessa Ostyn, Wenxin Huang et al.
2026-09 · DOI: 10.1016/j.jhep.2026.04.002Emerging strategies for hepatocellular carcinoma surveillance: abbreviated MRI, biomarkers and benefit stratification
George N. Ioannou, Peter Jepsen, Ian A. Rowe
2026-09 · DOI: 10.1016/j.jhep.2026.08.027Submit your abstract for the EASL Liver Cancer Summit 2027 by 13 October!
2026-09 · DOI: 10.1016/s0168-8278(26)02724-8Arachidonoyl-taurine is elevated in human MASLD and protects against hepatic steatosis and inflammation in preclinical models
Katharina B. Kuentzel, Samuel A.J. Trammell, Anna S. Hassing, Ivan Bradić et al.
2026-09 · DOI: 10.1016/j.jhep.2026.04.033Histopathology matters for imaging and clinical correlations in primary sclerosing cholangitis
Peter Schirmacher, Thomas Longerich
2026-09 · DOI: 10.1016/j.jhep.2026.05.012Reviews
Community Reviews
Version History
April 13, 2025 at 5:06 pm
April 13, 2025